second gen. oral troponin activator

Ph. III candidate for ALS (300 mg BID)

from HTS in muscle assay and reducing BP

Journal of Medicinal Chemistry

Cytokinetics, South San Francisco, CA

Chemical structure of molecule reldesemtiv

The Cytokinetics second generation troponin activator, reldesemtiv, is intended to treat muscle weakness by directly activating skeletal muscle. A high concentration of free drug is expected to be needed due…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: